Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Journal for ImmunoTherapy of Cancer2025Vol. 13(9), pp. e012747–e012747
Meredith M. Regan, Paolo A. Ascierto, Evan J. Lipson, Jennell Palaia, Andriy Moshyk, A. Selvan, Christopher D. Lao, Michael B. Atkins, David F. McDermott, Ravi Potluri, Sandip Ranjan, Sandeep Bilthare, Georgina V. Long, F Stephen Hodi, Hussein A. Tawbi, Dirk Schadendorf
Abstract
This analysis demonstrated TFS benefit during the 48 months since initiating nivolumab plus relatlimab compared with nivolumab alone in patients with advanced melanoma. A direct comparison between nivolumab plus relatlimab and nivolumab plus ipilimumab is needed to determine the differences between the regimens in TFS and those in traditional endpoints.
Related Papers
- → Nivolumab success in untreated metastatic melanoma(2014)24 cited
- → Case Report: Recurrent supraglottitis in a patient with metastatic melanoma treated with ipilimumab and nivolumab(2025)2 cited
- → Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review(2017)19 cited
- → LBA47 Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study(2024)3 cited
- → Ipilimumab + nivolumab in combination vs. nivolumab monotherapy as first-line treatment in patients with metastatic melanoma: conclusions from a real-world French national cohort(2025)